Clinical trial · Interventional
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix (Kit for the Preparation of Ga-68 PSMA-11 Injection)
NCT05558956CI-TRIAL-00068309unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Castration-resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| illuccix 68Ga-PSMA-11 Total Body PET-CT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Low Dose
- description
- 3 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
- interventionNames
- Drug: illuccix 68Ga-PSMA-11 Total Body PET-CT
- type
- EXPERIMENTAL
- label
- High dose
- description
- 7 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
- interventionNames
- Drug: illuccix 68Ga-PSMA-11 Total Body PET-CT
Primary outcomes (1)
- measure
- Comparing the imaging quality using low dose and high dose Ga-68 PSMA-11 at various scan lengths.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Male ≥ 18 years of age 3. Patients meeting clinical need for Illuccix PET scan: 1. Patients with suspected metastasis who are candidates for initial definitive therapy 2. Patients with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level 4. Patient is physically able to lay flat for the PET-CT procedure Exclusion Criteria: 1\. Assessment by the Investigator as unable or unwilling to comply with the requirements of the protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.